UBS Maintains Buy on Cardinal Health, Raises Price Target to $295
UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:CAH) with a Buy and raises the price target from $280 to $295.
Stocks · News reference
Cardinal Health Affirms FY2027 Adj EPS Of $12.40-$12.60 vs $12.04 Est
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.
China Patient Examination Devices Market Size, Share, and Forecast to 2033 - Thermometers and Stethoscopes | Pricing Trends and Growth Opportunities Guide Expansion
A comprehensive market report on China's patient examination devices market covering thermometers and stethoscopes through 2033. The report provides revenue, volume, and pricing data for medical device manufacturers, investors, and healthcare stakeholders, with 2025 company share analysis and competitive intelligence on key market players.
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation.